Anti-cancer activity of the HIV accessory molecule viral protein R (Vpr): Delivery as a DNA expression plasmid or biologically active peptides

Vaccine

Volumn 28, Issue 8, 2010, Pages 2005-2010

  Muthumani, Karrupiah ^a   Lambert, Vance M ^b   Kawalekar, Omkar ^a   Heller, Richard ^c   Kim, J Joseph ^d   Weiner, David B ^a   Ugen, Kenneth E ^b,e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c OLD DOMINION UNIVERSITY   (United States)

^d Inovio Biomedical Corporation   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cancer; Electroporation; Vpr

Indexed keywords

DNA; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; PEPTIDE; VPR PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; GENE EXPRESSION; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL;

ANIMALS; CANCER VACCINES; CELL PROLIFERATION; ELECTROPORATION; HELA CELLS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; PLASMIDS; VACCINES, DNA; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 76949097654     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.060     Document Type: Article

References (41)

1. Andersen J.L., Le Rouzic E., and Planelles V. HIV-1 Vpr: mechanisms of G2 arrest and apoptosis. Exp Mol Pathol 85 1 (2008) 2-10
2. Tungaturthi P.K., Sawaya B.E., Singh S.P., Tomkowicz B., Ayyavoo V., Khalili K., et al. Role of HIV-1 Vpr in AIDS pathogenesis: relevance and implications of intravirion, intracellular and free Vpr. Biomed Pharmacother 57 1 (2003) 20-24
3. Pang S., Kang M.K., Kung S., Yu D., Lee A., Poon B., et al. Anticancer effect of a lentiviral vector capable of expressing HIV-1 Vpr. Clin Cancer Res 7 11 (2001) 3567-3573
4. Shostak L.D., Ludlow J., Fisk J., Pursell S., Rimel B.J., Nguyen D., et al. Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1 vpr. Exp Cell Res 251 1 (1999) 156-165
5. Siddiqui K., Del Valle L., Morellet N., Cui J., Ghafouri M., Mukerjee R., et al. Molecular mimicry in inducing DNA damage between HIV-1 Vpr and the anticancer agent, cisplatin. Oncogene 27 1 (2008) 32-43
6. Stewart S.A., Poon B., Jowett J.B., Xie Y., and Chen I.S. Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells. Proc Natl Acad Sci USA 96 21 (1999) 12039-12043
7. Toy E.P., Rodriguez-Rodriguez L., McCance D., Ludlow J., and Planelles V. Induction of cell-cycle arrest in cervical cancer cells by the human immunodeficiency virus type 1 viral protein R. Obstet Gynecol 95 1 (2000) 141-146
8. Mahalingam S., MacDonald B., Ugen K.E., Ayyavoo V., Agadjanyan M.G., Williams W.V., et al. In vitro and in vivo tumor growth suppression by HIV-1 Vpr. DNA Cell Biol 16 2 (1997) 137-143
9. McCray A.N., Ugen K.E., and Heller R. Enhancement of anti-melanoma activity of a plasmid expressing HIV-1 Vpr delivered through in vivo electroporation. Cancer Biol Ther 6 8 (2007) 1269-1275
10. McCray A.N., Ugen K.E., Muthumani K., Kim J.J., Weiner D.B., and Heller R. Complete regression of established subcutaneous B16 murine melanoma tumors after delivery of an HIV-1 Vpr-expressing plasmid by in vivo electroporation. Mol Ther 14 5 (2006) 647-655
11. Muthumani K., Choo A.Y., Hwang D.S., Ugen K.E., and Weiner D.B. HIV-1 Vpr: enhancing sensitivity of tumors to apoptosis. Curr Drug Deliv 1 4 (2004) 335-344
12. Muthumani K., Lambert V.M., Sardesai N.Y., Kim J.J., Heller R., Weiner D.B., et al. Analysis of the potential for HIV-1 Vpr as an anti-cancer agent. Curr HIV Res 7 2 (2009) 144-152
13. Muthumani K., Lambert V.M., Shanmugam M., Thieu K.P., Choo A.Y., Chung J.C., et al. Anti-tumor activity mediated by protein and peptide transduction of HIV viral protein R (Vpr). Cancer Biol Ther 8 2 (2009) 180-187
14. Levy D.N., Fernandes L.S., Williams W.V., and Weiner D.B. Induction of cell differentiation by human immunodeficiency virus 1 vpr. Cell 72 4 (1993) 541-550
15. Heller R., Jaroszeski M., Atkin A., Moradpour D., Gilbert R., Wands J., et al. In vivo gene electroinjection and expression in rat liver. FEBS Lett 389 3 (1996) 225-228
16. Nishi T., Yoshizato K., Yamashiro S., Takeshima H., Sato K., Hamada K., et al. High-efficiency in vivo gene transfer using intraarterial plasmid DNA injection following in vivo electroporation. Cancer Res 56 5 (1996) 1050-1055
17. Glasspool-Malone J., Somiari S., Drabick J.J., and Malone R.W. Efficient nonviral cutaneous transfection. Mol Ther 2 2 (2000) 140-146
18. Heller L., Pottinger C., Jaroszeski M.J., Gilbert R., and Heller R. In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res 10 6 (2000) 577-583
19. Heller L.C., Ugen K., and Heller R. Electroporation for targeted gene transfer. Expert Opin Drug Deliv 2 2 (2005) 255-268
20. Kishida T., Asada H., Itokawa Y., Yasutomi K., Shin-Ya M., Gojo S., et al. Electrochemo-gene therapy of cancer: intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice. Mol Ther 8 5 (2003) 738-745
21. Lucas M.L., Heller L., Coppola D., and Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 5 6 (2002) 668-675
22. Lucas M.L., and Heller R. IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma. DNA Cell Biol 22 12 (2003) 755-763
23. Muramatsu T., Shibata O., Ryoki S., Ohmori Y., and Okumura J. Foreign gene expression in the mouse testis by localized in vivo gene transfer. Biochem Biophys Res Commun 233 1 (1997) 45-49
24. Niu G., Heller R., Catlett-Falcone R., Coppola D., Jaroszeski M., Dalton W., et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 59 20 (1999) 5059-5063
25. Ugen K.E., Kutzler M.A., Marrero B., Westover J., Coppola D., Weiner D.B., et al. Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation. Cancer Gene Ther 13 10 (2006) 969-974
26. Daud A.I., DeConti R.C., Andrews S., Urbas P., Riker A.I., Sondak V.K., et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26 36 (2008) 5896-5903
27. Laddy D.J., Yan J., Khan A.S., Andersen H., Cohn A., Greenhouse J., et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 83 9 (2009) 4624-4630
28. Vandermeulen G., Richiardi H., Escriou V., Ni J., Fournier P., Schirrmacher V., et al. Skin-specific promoters for genetic immunisation by DNA electroporation. Vaccine 27 32 (2009) 4272-4277
29. Chen T. Re-evaluation of HeLa, HeLaS3 and Hep-2 karyotypes. Cytogenet Cell Genet 48 (1988) 19-24
30. Frankel A.D., and Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55 6 (1988) 1189-1193
31. Green M., and Loewenstein P.M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55 6 (1988) 1179-1188
32. Latham P.W. Therapeutic peptides revisted. Nat Biotech 17 (1999) 755-757
33. Mann D.A., and Frankel A.D. Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J 10 7 (1991) 1733-1739
34. McGregor D.P. Discovering and improving novel peptide therapeutics. Curr Opin Pharmacol 8 5 (2008) 616-619
35. Nagahara H., Vocero-Akbani A.M., Snyder E.L., Ho A., Latham D.G., Lissy N.A., et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 4 12 (1998) 1449-1452
36. Prochiantz A. Messenger proteins: homeoproteins, TAT and others. Curr Opin Cell Biol 12 4 (2000) 400-406
37. Torchilin V.P., Levchenko T.S., Rammohan R., Volodina N., Papahadjopoulos-Sternberg B., and D'Souza G.G. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci USA 100 4 (2003) 1972-1977
38. Yao S., Torres A.M., Azad A.A., Macreadie I.G., and Norton R.S. Solution structure of peptides from HIV-1 Vpr protein that cause membrane permeabilization and growth arrest. J Pept Sci 4 7 (1998) 426-435
39. Yao X.J., Subbramanian R.A., Rougeau N., Boisvert F., Bergeron D., and Cohen E.A. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J Virol 69 11 (1995) 7032-7044
40. Loveland B.E., Johns T.G., Mackay I.R., Vaillant F., Wang Z.X., and Hertzog P.J. Validation of the MTT dye assay for enumeration of cells in proliferative and antiproliferative assays. Biochem Int 27 3 (1992) 501-510
41. Muthumani K., Zhang D., Hwang D.S., Kudchodkar S., Dayes N.S., Desai B.M., et al. Adenovirus encoding HIV-1 Vpr activates caspase 9 and induces apoptotic cell death in both p53 positive and negative human tumor cell lines. Oncogene 21 30 (2002) 4613-4625